Conferences & Events

Found 72,836 articles

• The Second Annual CA Community Opioid Conference Is On A Mission To Save Lives

  10/21/2019

  Social Model Recovery Systems, Inc., will be hosting the Second Annual California Community Opioid Conference at the Anaheim Convention Center, on November 21 and 22, 2019.

• RAPID Platform Expands to Address Hemorrhagic Stroke

  10/21/2019

  iSchemaView, the worldwide leader in advanced imaging for stroke, today launched the newest addition to the RAPID platform, RAPID ICH1 at the 2019 Congress of Neurological Surgeons (CNS) Annual Meeting.

• Medigate Named as Hot IoT Startup to Watch in Big50-2019 Startup Report

  10/21/2019

  Medigate has been named a “Hot Startup to Watch” in the Internet of Things (IoT) category for Startup50’s Big50-2019 Startup Report, which spotlights 50 startups that have gained a foothold in fast-growth tech sectors.

• Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

  10/21/2019

  Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present results from its pivotal Phase 3 CONFIRM study in a late-breaker session on Monday, Nov. 11 at 3:30 pm ET during The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

• Durability of Treatment Effect of Mirum Pharmaceuticals’ Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019

  10/21/2019

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that data on its program for the treatment of children with maralixibat will be featured in the late breaking oral presentation session during the American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 8-12, 2019, in Boston.

• Mycovia Pharmaceuticals to Present at 2019 BIO Investor Forum

  10/21/2019

  Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that Chief Executive Officer Patrick Jordan will present at the 2019 BIO Investor Forum being held October 22-23 at the Westin St. Francis in San Francisco, Calif.

• SpinalCyte to Present at the 2019 BIO Investor Forum

  10/21/2019

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, SpinalCyte's Chief Executive Officer, will present at the BIO Investor Forum on Tuesday, October 22, 2019 at 3:45 p.m. PDT in San Francisco, CA.

• Amplify Science Earns Prestigious Tier 1 Rating in Louisiana

  10/21/2019

  Amplify, a publisher of next-generation curriculum and assessment programs, announced today that Louisiana rated Amplify Science K–5 as Tier 1, the top rating in the state. Amplify Science is the only K–5 science program in the state to receive a Tier 1 rating

• Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

  10/21/2019

  Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that it will host a Key Opinion Leader (KOL) call on the role of CAP-1002 in the of treatment of Duchenne Muscular Dystrophy (DMD) on Thursday, October 24th at 10:30am Eastern Time.

• Histogen To Present At The BIO Investor Forum

  10/21/2019

  The event is being held October 22-23, 2019 at The Westin St. Francis in San Francisco.

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  10/21/2019

  Bayer today announced recipients of the inaugural Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

• NTI™ (Northgate Technologies, Inc.) Receives Innovative Technology Contract from Vizient for NEBULAE™ I System, High-flow Laparoscopic Insufflator

  10/21/2019

  NTI announced its NEBULAE™ I System, High-flow Laparoscopic Insufflator, has been awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country

• Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

  10/21/2019

  27th European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 22-25, 2019 in Barcelona, Spain.  

• Soliton to Announce Keloid Trial Data on October 25, 2019 and Host Webcast at 5:30PM ET to Discuss Results

  10/21/2019

  Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announces it will host a webcast to present the company's interim keloid and hypertrophic scar proof-of-concept ("POC") trial data on October 25, 2019 at 5:30 p.m. ET. 

• Goldfinch Bio Presents Methods to Mitigate Batch Effects in Whole Genome Sequencing Samples at ASHG 2019 Annual Meeting

  10/21/2019

  Data-driven approach enables well-calibrated dataset for case-control genome-wide association study in the Kidney Genome Atlas

• OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market

  10/21/2019

  Letter to Shareholders from CEO Daniel J. O'Connor regarding the recently-announced strategic transaction with Grand Decade Developments Limited, a direct wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (HKG:512) and its affiliate, Sirtex Medical US Holdings, Inc.

• Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies

  10/21/2019

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its investigational gene therapy programs for the treatment of metachromatic leukodystrophy (MLD) and phenylketonuria (PKU) at the American Society of Human Genetics (ASHG) 2019 Meeting.

• McKesson Hosts 2019 Onmark Summit for Community-Based Oncology Practices

  10/21/2019

  Attendees gained valuable insight into how to thrive in the changing oncology landscape

• Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract

  10/21/2019

  Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to provide a summary of the presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup.”

• ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting

  10/21/2019

  Treatment with miransertib prevents formation of new PIK3CA-driven vascular malformations and leads to regression of existing PIK3CA-driven vascular malformations in experimental mouse model